ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
On January 25, 2023, Carrie Anderson, Chief Financial Officer of Integra
LifeSciences Holdings Corporation (the "Company"), notified the Company of her
decision to resign, effective as of February 2, 2023, to pursue another
professional opportunity.
The Company intends to commence a comprehensive search process to identify a new
Chief Financial Officer. In the interim, Mathieu P. Aussermeier, Vice President,
Corporate Finance, Investor Relations & Treasurer, and Jeffrey Mosebrook, Senior
Vice President, Finance, will assume Ms. Anderson's financial duties and
responsibilities and report to Jan De Witte, the Company's President and Chief
Executive Officer. Mr. Aussermeier will be responsible for treasury, financial
planning and analysis, and investor relations. Mr. Mosebrook will oversee
accounting, tax, internal audit and global business services. During the interim
period, Mr. Mosebrook will serve as the Company's principal financial officer in
addition to serving as principal accounting officer.
Mr. Mosebrook's biographical information is described in the Company's
definitive proxy statement filed with the Securities and Exchange Commission on
April 8, 2022, which is incorporated herein by reference. There are no
arrangements or understandings between Mr. Mosebrook and any other person that
would require disclosure under Item 401(b) of Regulation S-K. Additionally,
there is no family relationship between Mr. Mosebrook and any other person that
would require disclosure under Item 401(d) of Regulation S-K and he is not a
party to any transactions that would require disclosure under Item 404(a) of
Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses